Zobrazeno 1 - 10
of 28
pro vyhledávání: '"I Cardona-Pascual"'
Autor:
D. Berlana, A. Pau Parra, A.E. García Fernández, J. Lopez Hellin, I. Cardona Pascual, J. Santander Reboreda, D. Anguita Domingo, J.B. Montoro Ronsano
Publikováno v:
Clinical Nutrition ESPEN. 54:675
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d5a3f67066b057bff1fe69893fd8cdf
https://doi.org/10.1016/j.clnesp.2022.09.638
https://doi.org/10.1016/j.clnesp.2022.09.638
Autor:
C Varon-Galcera, A Gracia-Moya, I Cardona Pascual, E Florensa Royo, J Vidal Otero, G Vancells Lujan, MQ Gorgas Torner
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaa664bdd5fd5712b107c7c1e3c42b2a
https://doi.org/10.1136/ejhpharm-2022-eahp.175
https://doi.org/10.1136/ejhpharm-2022-eahp.175
Autor:
E Serramontmany Morante, I Cardona-Pascual, P Garcia Ortega, M Carreras Soler, MQ Gorgas Torner, I Cidoncha Muñoz, E Felip Font
Publikováno v:
Section 6: Education and research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a27818c6cbfb8a1d338861bef7c617e5
https://doi.org/10.1136/ejhpharm-2022-eahp.366
https://doi.org/10.1136/ejhpharm-2022-eahp.366
Autor:
A Gracia Moya, C Varon Galcera, I Cardona Pascual, E Florensa Royo, J Vidal Otero, G Vancells Lujan, MQ Gorgas Torner
Publikováno v:
Section 7: Post Congress additions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ce2204332cfd21e42d27035ae7c4499
https://doi.org/10.1136/ejhpharm-2022-eahp.421
https://doi.org/10.1136/ejhpharm-2022-eahp.421
Autor:
M Miarons Font, A. Pau Parra, P Garcia Ortega, P Sánchez Sancho, I Cardona Pascual, B Torrecilla Vall-Llossera, MQ Gorgas Torner, A Gracia Moya
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Adalimumab (ADA), an anti-TNF agent, has been shown to effectively induce and maintain remission in patients with inflammatory bowel disease (IBD). The usual recommended dose in the maintenance phase is 40 mg every 14 days.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6378608efce8298b3cccd20c98661a0
https://doi.org/10.1136/ejhpharm-2021-eahpconf.154
https://doi.org/10.1136/ejhpharm-2021-eahpconf.154
Autor:
C Alonso Martinez, M Larrosa García, JB Montoro Ronsano, S Garcia Garcia, I. Cardona Pascual, E Revilla López, J Vidal Otero, L Cantos Gil, C Alerany Pardo, Gomez Domingo, P Granollers Rabal
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Aztreonam lysine inhalation solution (AZLI) is approved for nebulised treatment (nebT) of pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF). The clinical benefit of nebulised AZLI in non-CF, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b59f004011989569756dc0cbcaf65fe
https://doi.org/10.1136/ejhpharm-2020-eahpconf.134
https://doi.org/10.1136/ejhpharm-2020-eahpconf.134
Autor:
R Caparros Ruiz, M Larrosa García, S Garcia Garcia, C Alonso Martinez, I. Cardona Pascual, C Alerany Pardo, J Vidal Otero, JB Montoro Ronsano, Gomez Domingo, S Gamarra Calvo
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Tofacitinib and baricitinib are oral Janus kinase inhibitors (JKi) approved for the treatment of rheumatoid arthritis (RA), offering an alternative in patients who have not responded or tolerated previous treatment lines bec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb1f3f2321c7d4dc0bd55ccd06bf91bd
https://doi.org/10.1136/ejhpharm-2020-eahpconf.220
https://doi.org/10.1136/ejhpharm-2020-eahpconf.220
4CPS-019 Alirocumab and evolocumab: effectiveness after 3 years of follow-up in a real world setting
Autor:
M Gomez-Domingo, C Alonso Martinez, Silvia García-García, I Cardona-Pascual, M Larrosa-Garcia, M Gorgas-Torner, C Alerany Pardo, J Vidal-Otero, M Miarons-Font, P Sanchez-Sanchez
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Hypercholesterolaemia leads to a higher risk of atherosclerosis and cardiovascular events. Familial hypercholesterolaemia is more resistant to usual treatments. In 2015, the PCSK9 inhibitors (PCSK9I) alirocumab and evolocuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46b4f72f7924652a1a2d7c3eb73d0f14
https://doi.org/10.1136/ejhpharm-2020-eahpconf.120
https://doi.org/10.1136/ejhpharm-2020-eahpconf.120
Publikováno v:
Section 1: Introductory Statements and Governance.
Background Biosimilars are a great opportunity to improve the efficiency of health systems. Their quality is certified by regulatory agencies and high-quality clinical trials. However, some reluctance about switching between originals and biosimilars
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4098cedfe23757334cb8e82262790d6
https://doi.org/10.1136/ejhpharm-2019-eahpconf.24
https://doi.org/10.1136/ejhpharm-2019-eahpconf.24
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.